Announcements Trials

Conditions

Gynecologic 5Thoracic 5Other 4Gastrointestinal 3Genitourinary 2Head & Neck 2

Drug Classes

Anti-PD-1 13PARP inhibitor 6Platinum agent 5Taxane 5Anti-FOLR1 ADC 2Anti-TF ADC 2Anti-VEGFR 2Anti-HER2 ADC 1Anti-PD-L1 1BRAF inhibitor 1Glucocorticoid receptor antagonist 1MEK inhibitor 1Multi-ingredient 1Multikinase inhibitor 1RET inhibitor 1ROS1 inhibitor 1TRK inhibitor 1Topoisomerase I inhibitor 1
Platinum agent × Gynecologic × Clear all

5 Announcements

2024-08-01

FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Trial
RUBY
Drugs
Jemperli (dostarlimab-gxly) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition
Gynecologic
2024-06-17

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma

Drugs
Keytruda (pembrolizumab) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition
Gynecologic
2023-07-31

FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer

Trial
RUBY
Drugs
Jemperli (dostarlimab-gxly) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition
Gynecologic
2018-06-13

FDA approves bevacizumab in combination with chemotherapy for ovarian cancer

Drugs
Avastin (bevacizumab) · Anti-VEGFR antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition
Gynecologic
2006-06-14

FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix

Drugs
Hycamtin (topotecan hydrochloride) · Topoisomerase I inhibitor, cisplatin · Platinum agent
Condition
Gynecologic
Data powered by HemOnc (CC BY 4.0) Colophon ⚡